Abstract:Abstract Background We suggest an adaptive sample size calculation method for developing clinical prediction models, in which model performance is monitored sequentially as new data comes in. Methods We illustrate the approach using data for the diagnosis of ovarian cancer ( n = 5914, 33% event fraction) and obstructive coronary artery disease (CAD; n = 4888, 44% event fraction). We used logistic regression to develop a prediction model consisting only of a priori selected predictors and assumed linear relations for continuous predictors. We mimicked prospective patient recruitment by developing the model on 100 randomly selected patients, and we used bootstrapping to internally validate the model. We sequentially added 50 random new patients until we reached a sample size of 3000 and re-estimated model performance at each step. We examined the required sample size for satisfying the following stopping rule: obtaining a calibration slope ≥ 0.9 and optimism in the c-statistic (or AUC) < = 0.02 at two consecutive sample sizes. This procedure was repeated 500 times. We also investigated the impact of alternative modeling strategies: modeling nonlinear relations for continuous predictors and correcting for bias on the model estimates (Firth’s correction). Results Better discrimination was achieved in the ovarian cancer data (c-statistic 0.9 with 7 predictors) than in the CAD data (c-statistic 0.7 with 11 predictors). Adequate calibration and limited optimism in discrimination was achieved after a median of 450 patients (interquartile range 450–500) for the ovarian cancer data (22 events per parameter (EPP), 20–24) and 850 patients (750–900) for the CAD data (33 EPP, 30–35). A stricter criterion, requiring AUC optimism < = 0.01, was met with a median of 500 (23 EPP) and 1500 (59 EPP) patients, respectively. These sample sizes were much higher than the well-known 10 EPP rule of thumb and slightly higher than a recently published fixed sample size calculation method by Riley et al. Higher sample sizes were required when nonlinear relationships were modeled, and lower sample sizes when Firth’s correction was used. Conclusions Adaptive sample size determination can be a useful supplement to fixed a priori sample size calculations, because it allows to tailor the sample size to the specific prediction modeling context in a dynamic fashion.

Sample size determination for biomedical big data with limited labels

Sample size determination for prediction models via learning‐type curves

Sample Size in Natural Language Processing within Healthcare Research

Sample size and statistical power considerations in high-dimensionality data settings: a comparative study of classification algorithms

Optimizing Sample Size for Supervised Machine Learning with Bulk Transcriptomic Sequencing: A Learning Curve Approach

Sample size planning for classification models

Logistic regression models for patient-level prediction based on massive observational data: Do we need all data?

Sample size determination for training cancer classifiers from microarray and RNA-seq data

Addressing statistical challenges in the analysis of proteomics data with extremely small sample size: a simulation study

Big data in medical science--a biostatistical view

An evaluation of sample size requirements for developing risk prediction models with binary outcomes

Sample size determination for multidimensional parameters and the A-optimal subsampling in a big data linear regression model

Adaptive sample size determination for the development of clinical prediction models

Evaluation of a decided sample size in machine learning applications

Sample size for developing a prediction model with a binary outcome: targeting precise individual risk estimates to improve clinical decisions and fairness

Sampling techniques for big data analysis in finite population inference

Calculating the sample size required for developing a clinical prediction model

A Multi-Armed Bandit to Smartly Select a Training Set from Big Medical Data

Automatically Labeling $200B Life-Saving Datasets: A Large Clinical Trial Outcome Benchmark

Efficient Biological Data Acquisition through Inference Set Design

Revisiting Sample Size Determination in Natural Language Understanding